Opinion|Videos|August 5, 2024
Improving Insurance Coverage for RSV Vaccines
The panel discusses what’s needed for payers to activate early coverage for RSV vaccines in adults and how coverage has been since the approval of the 2 RSV vaccines.
Advertisement
Episodes in this series
Video content above is prompted by the following questions:
- With RSV season shifting earlier in the year and hospitalization rates increasing, what is needed for payers to activate early coverage for RSV vaccines in adults?
- How has the recommendation from the ACIP (Advisory Committee on Immunization Practices) impacted coverage of an RSV vaccine?
- How has coverage by insurance companies been since the approval (60+) of the 2 RSV vaccines?
- How can potential insurance coverage for RSV vaccines for those between 50-59 be optimized?
- How can potential insurance coverage for RSV vaccines for those between 50-59 be optimized?
Advertisement
Related to this article
Bispecific programs differ by practice size, but shared core components can guide adaptation, experts said at a webinar for the Bispecifics Network.
Bipolar disorder often goes undiagnosed for years, and clinicians need to separate mood episodes from normal emotions and keep patients on treatment.
A phase 4 study found 69% of patients with OAB were consistently satisfied with vibegron at 12 months, with exploratory persistence of 59.8%.
Two machine learning models identifies MASLD in lean adults using 8 routine clinical measurements.
Pharmacists are moving beyond order verification into patient education, adverse effect mitigation, and parts of toxicity triage in bispecific care.
Weekly gefurulimab cut MG-ADL scores by 4.2 points vs 2.6 with placebo at week 26 in adults with generalized myasthenia gravis in the PREVAIL study.
Meta-analysis suggests off-label upadacitinib drives major alopecia areata hair regrowth and SALT score gains, but phase 3 trials show lower responses.
Kidney Week 2026 brought strong IgAN data, looked back on 5 years of value-based kidney care, and highlighted evidence of persistent CKD care gaps.
Advertisement
Advertisement
Trending on AJMC
1
HHS Draft Policy Eases Enforcement on 6 Compounded Peptides
2
Four Major Idiopathic Pulmonary Fibrosis Advances From 2026
3
5 Things to Know About HHS's Interim Peptide Compounding Policy
4
Elagolix Noninferior to Dienogest for Endometriosis Pain in Phase 3 Trial
5